Talking About a New Investigational Drug for ET

Sage 324 is an oral investigational drug which is thought to enhance the activity of GABA receptors in the brain tremor, having the potential to modulate electrical fluctuations and reduce the abnormal movements in essential tremor. Listen to this podcast with Helen Colquhoun , VP of Development with Sage Therapeutics.

Tags:
Categories: Podcasts

11 thoughts on “Talking About a New Investigational Drug for ET

    1. We have two in Illinois. They are in Aurora and in Winfield. However, many are meeting online during COVID. If you want to reach out to one of these, here is the contact information: Aurora, IL Support Group leader is Christine Weincek, cweincek@rushcopley.com. The Winfield, IL Support Group leader is Lynn Bernau, lbb1219@yahoo.com.

  1. As a ET person, we need a medication specifically for ET. None of the meds prescribed by neurology doctors have worked for me. Only gave me bad side effects.

    1. Do you have a cell phone? That might be another avenue for listening to it. Sorry you are having trouble accessing it.

  2. Have had ET for over 40 years, with head tremor, then left arm tremor, and now recently right arm (dominant) tremor. Have been on Propranolol ER and Primidone for years, but tremors continue. I am now 68 and looking into Botox injections in my neck for the head tremor. Would be interested in information about Sage 324 as trials progress.

  3. Does anyone have any updates on the study that was supposed to be conducted at the University of California School of Medicine who were “to launch a novel clinical trial to examine the safety, efficacy and pharmacological properties of cannabis as a potential treatment for adults with essential tremor (ET). Currently, ET is treated using repurposed medications originally developed for high blood pressure or seizures. Surgery is another option.
    Scheduled for early 2019, the phase I/II trial will assess efficacy and tolerability of an oral cannabis formulation comprised of cannabidiol (CBD) and low-dose tetrahydrocannabinol (THC). “

    1. The study experienced several delays due to Canadian regulatory approvals to permit export of the product to the U.S.(it was not available in the U.S. so the university had to reach out to a company in Canada). Recruitment was also challenging, then COVID happened which halted it for a while. We just learned that a report about the study will be published in the spring. We’ll be sure to post it and share it with everyone.

Leave a Reply

Your email address will not be published. Required fields are marked *